125000.

 (a) It is the policy of the State of California to make every effort to detect, as early as possible, phenylketonuria and other preventable heritable or congenital disorders leading to intellectual disability or physical defects.

The department shall establish a genetic disease unit, that shall coordinate all programs of the department in the area of genetic disease. The unit shall promote a statewide program of information, testing, and counseling services and shall have the responsibility of designating tests and regulations to be used in executing this program.

The information, tests, and counseling for children shall be in accordance with accepted medical practices and shall be administered to each child born in California once the department has established appropriate regulations and testing methods. The information, tests, and counseling for pregnant women shall be in accordance with accepted medical practices and shall be offered to each pregnant woman in California once the department has established appropriate regulations and testing methods. These regulations shall follow the standards and principles specified in Section 124980. The department may provide laboratory testing facilities or contract with any laboratory that it deems qualified to conduct tests required under this section. However, notwithstanding former Section 125005, provision of laboratory testing facilities by the department shall be contingent upon the provision of funding therefor by specific appropriation to the Genetic Disease Testing Fund enacted by the Legislature. If moneys appropriated for purposes of this section are not authorized for expenditure to provide laboratory facilities, the department may nevertheless contract to provide laboratory testing services pursuant to this section and shall perform laboratory services, including, but not limited to, quality control, confirmatory, and emergency testing, necessary to ensure the objectives of this program.

(b) The department shall charge a fee for any tests performed pursuant to this section. The amount of the fee shall be established and periodically adjusted by the director in order to meet the costs of this section.

(c) The department shall inform all hospitals or physicians and surgeons, or both, of required regulations and tests and may alter or withdraw any of these requirements whenever sound medical practice so indicates. To the extent practicable, the department shall provide notice to hospitals and other payers in advance of an increase in the fees charged for the program.

(d) This section shall not apply if a parent or guardian of the newborn child objects to a test on the ground that the test conflicts with his or her religious beliefs or practices.

(e) The genetic disease unit is authorized to make grants or contracts or payments to vendors approved by the department for all of the following:

(1) Testing and counseling services.

(2) Demonstration projects to determine the desirability and feasibility of additional tests or new genetic services.

(3) To initiate the development of genetic services in areas of need.

(4) To purchase or provide genetic services from any sums as are appropriated for this purpose.

(f) The genetic disease unit shall evaluate and prepare recommendations on the implementation of tests for the detection of hereditary and congenital diseases, including, but not limited to, biotinidase deficiency and cystic fibrosis. The genetic disease unit shall also evaluate and prepare recommendations on the availability and effectiveness of preventative followup interventions, including the use of specialized medically necessary dietary products.

It is the intent of the Legislature that funds for the support of the evaluations and recommendations required pursuant to this subdivision, and for the activities authorized pursuant to subdivision (e), shall be provided in the annual Budget Act appropriation from the Genetic Disease Testing Fund.

(g) Health care providers that contract with a prepaid group practice health care service plan that annually has at least 20,000 births among its membership, may provide, without contracting with the department, any or all of the testing and counseling services required to be provided under this section or the regulations adopted pursuant thereto, if the services meet the quality standards and adhere to the regulations established by the department and the plan pays that portion of a fee established under this section that is directly attributable to the department’s cost of administering the testing or counseling service and to any required testing or counseling services provided by the state for plan members. The payment by the plan, as provided in this subdivision, shall be deemed to fulfill any obligation the provider or the provider’s patient may have to the department to pay a fee in connection with the testing or counseling service.

(h) The department may appoint experts in the area of genetic screening, including, but not limited to, cytogenetics, molecular biology, prenatal, specimen collection, and ultrasound to provide expert advice and opinion on the interpretation and enforcement of regulations adopted pursuant to this section. These experts shall be designated agents of the state with respect to their assignments. These experts shall receive no salary, but shall be reimbursed for expenses associated with the purposes of this section. All expenses of the experts for the purposes of this section shall be paid from the Genetic Disease Testing Fund.

125003.

 (a) The department shall prepare and provide informational materials regarding newborn child blood samples collected pursuant to this article that include, but are not limited to, all of the following:

(1) A brief, plain-language explanation of, and the purpose for, the newborn child screening test and the storage, retention, and use of newborn child blood samples collected pursuant to this article, including that the samples may be shared with third parties for research purposes.

(2) A description of the benefits of both early newborn child screening and the associated research undertaken regarding preventable heritable or congenital disorders.

(3) A description of the California Biobank Program, specifically as it pertains to the Genetic Disease Screening Program, and subsequent storage, retention, and use of the newborn child’s blood sample for medical research.

(4) The parent or legal guardian’s right to refuse the test based on their religious beliefs.

(5) The parent or legal guardian’s right to withhold consent for their minor child’s blood sample to be stored and used for research purposes.

(6) The parent or legal guardian’s right to request that their minor child’s blood sample be destroyed, not used for research purposes, or both, if the parent or legal guardian has initially consented to the sample being stored and used for research purposes at the time the sample is taken, and the information necessary to make that request.

(7) The right of an individual who is at least 18 years of age to request that their blood sample be destroyed, not used for research purposes, or both, and the information necessary to make that request.

(b) These informational materials shall be confined to a single page and presented in a separate document from the standard informational acceptance, consent, or refusal form required in Section 125004.

125004.

 (a) The department shall prepare a separate standard informational acceptance, consent, and refusal form that includes all of the following:

(1) (A) A brief, plain-language explanation of, and the purpose for, the newborn child screening test and retention of newborn child blood samples collected pursuant to this article, including that the samples may be shared with third parties for research purposes.

(B) An explanation of the parent’s or legal guardian’s right to request that their minor child’s blood sample be destroyed or not used for research purposes, or both, if the parent or legal guardian has initially consented to the sample being stored and used for research purposes at the time the sample is taken, and the information necessary to make that request.

(C) A space for the parent or legal guardian of the newborn child to provide a signed and dated written acknowledgment of receipt of informational materials regarding the storage, retention, and use of the newborn child’s blood sample for medical research.

(2) (A) A space for the parent or legal guardian of the newborn child to provide signed consent for the storage of the newborn blood sample.

(B) A space for the parent or legal guardian of the newborn child to provide signed consent for the storage and use of the newborn blood sample for research purposes.

(C) A space for the parent or legal guardian of the newborn child to refuse the newborn screening test on their newborn or infant for religious reasons.

(b) The standard form shall be confined to a single page and presented in a separate document from the informational materials required in Section 125003.

(c) A copy of the signed standard form shall be maintained in the medical record of the mother of the newborn child.

(d) As used in this article, “informational acceptance, consent, and refusal form” or “standard form” means a written acknowledgment of received informational materials, written consent to storage and use of newborn blood sample for research, and refusal of the newborn screening test, if applicable, signed and dated by a parent or legal guardian of a newborn child.

(e) In the event that emergency circumstances make it impossible to obtain the signed standard form, a note shall be placed in the medical record of the mother documenting the emergency or reason why the form could not be obtained, and the newborn child shall be administered the genetic screening test and the newborn child blood sample shall be stored and retained for medical research pursuant to Section 125000.

125005.

 (a) The department shall provide a parent or legal guardian with the informational materials described in Section 125003 and the standard form described in Section 125004 regarding the retention of newborn child blood samples collected pursuant to this article.

(b) The standard form described in Section 125004 shall be distributed as follows:

(1) A birth attendant engaged in providing perinatal care shall provide a pregnant woman, at least four weeks prior to the estimated date of delivery, with a copy of the informational materials and a copy of the standard form provided by the department.

(2) If the informational materials or standard form has not been provided pursuant to paragraph (1), a perinatal licensed health facility shall provide each pregnant woman admitted for delivery with a copy of the informational materials and a copy of the standard form provided by the department.

(3) The local registrar of births and deaths shall provide a copy of the informational material and a copy of the standard form provided by the department to each person registering the birth of a newborn that occurred outside of a perinatal licensed health facility when the newborn was not admitted to a perinatal licensed health facility within the first 30 days after birth. The local registrar of births and deaths shall notify the local health officer and the department of each of these registrations.

(c) For the purposes of this section, the following terms shall have the following meanings:

(1) “Birth attendant” means a person licensed or certified by the state to provide maternity care and to deliver pregnant women or to practice medicine.

(2) “Perinatal licensed health facility” means a health facility licensed by the state and approved to provide perinatal, delivery, newborn intensive care, newborn nursery, or pediatric services.